Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Adavosertib + Carboplatin||Phase I||Actionable||In a Phase I trial, the combination of Adavosertib (MK-1775) and Paraplatin (carboplatin) resulted in a partial response in 6.5% (4/62) of patients and stable disease in 45% (28/62) of patients, all with advanced solid tumors (PMID: 27601554).||27601554|
|Unknown unknown||Advanced Solid Tumor||not applicable||Adavosertib + Carboplatin||Phase Ib/II||Actionable||In a Phase Ib trial, Adavosertib (MK-1775) in combination with Paraplatin (carboplatin) was tolerable and resulted in partial response in 16.7% (1/3) of patients and stable disease in 33.3% (2/6) of Asian patients with advanced solid tumors (PMID: 32034630).||32034630|
|PubMed Id||Reference Title||Details|
|(27601554)||Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.||Full reference...|
|(32034630)||Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.||Full reference...|